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a-Adducin polymorphisms and renal sodium handling in essential
hypertensive patients. The relationship between blood pressure and
sodium (Na) excretion is less steep in hypertension caused by increased
renal tubular reabsorption. We recently demonstrated that one mutation
in rat a-adducin gene: (1) is responsible for approximately 50% of the
hypertension of MHS rats, and (2) stimulates tubular Na-K pump activity
when transfected in renal epithelial cell, suggesting that its pressor effect
may occur because an increased tubular reabsorption. Linkage and
association studies demonstrated that the a-adducin locus is relevant for
human hypertension. A point mutation (G460W) was found in human
a-adducin gene, the 460W variant (G/W) is more frequent in hyperten-
sives than in normotensives. The aim of this study was to test whether
acute changes in body Na may differently affect blood pressure in humans
as a function of a-adducin genotype. The pressure-natriuresis relationship
was analyzed in 108 hypertensives using two different acute maneuvers:
Na removal (furosemide 25 mg p.o.) and, two days later, Na load (310
mmoles i.v. in 2 hr). We found that 80 patients were wild-type homozygous
(G/G), 26 were G/W heterozygous, and 2 were W/W homozygous with
similar blood pressure, age, body mass index, gender, plasma and urinary
sodium and potassium. In basal condition G/W-W/W patients showed a
lower plasma renin activity and fractional excretion of Na. In either case
the pressure-natriuresis relationship was less steep in G/W-W/W than in
G/G patients, obviously negative for Na depletion with furosemide
(20.011 6 0.004 vs. 20.002 6 0.002 mm Hg/mmol/min, P , 0.03), and
positive for Na load (0.086 6 0.02 vs. 0.027 6 0.007 mm Hg/mmol/min, P ,
0.001). The finding of reduced slope after Na depletion or Na load
supports the hypothesis that, as MHS rats, humans bearing one W
a-adducin variant display an increased of renal tubular sodium reabsorp-
tion.
The renal pressure-natriuresis relationship is less steep or
shifted rightward in arterial hypertension [1]. This abnormality
may be caused by either intrarenal or extrarenal factors, which
affect renal blood flow (RBF), glomerular filtration rate (GFR),
or tubular reabsorption. The characteristics of this relationship
are different according to the renal mechanisms involved [1]. In
fact, the increase in tubular reabsorption, or reduced GFR,
produce a decrease in the slope of the relationship, as it is
observed in salt sensitive forms of primary hypertension or in
patients with mineralocorticoid excess. Reduced RBF produces a
rightward shift of this relationship. These characteristics may help
in establishing the type of underlying renal function abnormality
that is at work in a particular subset of patients [1–4].
During the last 20 years our group has carried out a series of
studies comparing the Milan hypertensive rats (MHS) with the
normotensive control strain (MNS) [5, 6]. These studies demon-
strated that hypertension develops in MHS because of a primary
increase in renal tubular sodium reabsorption [6–8], and that a
functional point mutation within the gene coding for a-adducin
may be responsible for increased tubular reabsorption and for a
significant portion of the blood pressure difference between MHS
and MNS [9–11]. Adducin is a cytoskeleton protein involved in
the formation of actin-spectrin lactice, actin polymerization and
cell signal transduction [12–14]. Transfection of either MHS or
MNS a-adducin cDNA into rat renal epithelial cells showed that
cells expressing MHS adducin had a significantly greater Na pump
activity at Vmax and a larger number of Na pump units expressed
on the cell surface [15]. Therefore, a link between molecular
adducin variants and tubular Na reabsorption could be suggested.
In humans, the results of two case-control studies and a sibling-
pair analysis were consistent with the findings in rats [16, 17].
These studies showed that a functional point mutation in the
a-adducin coding region G460W was associated with hyperten-
sion and with a greater decrease in blood pressure after long-term
thiazide treatment or acute Weinberger’s test [18], thus support-
ing the notion that adducin may affect blood pressure through
changes in renal Na handling. If the mutated human adducin
variant causes hypertension by increasing tubular reabsorption, as
it has been demonstrated for the rat variant, hypertensive indi-
viduals carrying at least one copy of the mutated variant should
have a less steep pressure natriuresis curve than those with the
wild variant. The pressure natriuresis relationship reflects the
influence of blood pressure on sodium excretion. Therefore,
animal data were produced by analyzing the changes of Na
excretion as a function of blood pressure; however, in humans
chronic and acute studies are performed by analyzing the blood
pressure changes as a function of Na intake or excretion [1, 3, 4].
In this study our hypothesis was tested analyzing blood pressure
changes after Na depletion (25 mg furosemide p.o.) and after Na
load (310 mmoles i.v.) as a function of a-adducin genotype in 108
patients with essential hypertension. The results showed that the
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460W adducin variant is associated with a reduced slope of the
pressure-natriuresis relationship.
METHODS
Patient selection
One hundred and twenty-three essential hypertensive patients
were randomly recruited from one of our outpatient clinics by two
of us (P.M. and M.R.) after having excluded: (i) patients with a
history of myocardial infarction, congestive heart failure, stroke,
creatinine clearance , 80 ml/min, diabetes mellitus, liver disease;
(ii) severe hypertension requiring treatment; (iii) women on oral
contraceptives; and (iv) individuals known to abuse drugs or
alcohol. A large number of them (N 5 65) had a recent diagnosis
of hypertension, and had never been treated before with antihy-
pertensive drugs. Treated patients discontinued any medication
for at least four months. During this period, blood pressure was
monitored every two to three weeks and therapy was started.
Patients were consequently excluded from the study if diastolic
blood pressure reached 110 mm Hg (N 5 6). The office blood
pressure was greater than 145/95 mm Hg, at least on three
occasions, in the patients enrolled in the study. A 24-hour
ambulatory blood pressure recording (24-hr ABPM, Spacelabs
90207) was performed in all patients to confirm the diagnosis of
hypertension. Patients with mean daytime blood pressures .
140/90 mm Hg were included. All patients were advised on the
appropriate diet to maintain a stable Na content of about 150
mmol/day.
The study was approved by the Ethical Committee of the San
Raffaele Hospital. Informed consent to this study was always
obtained from each individual enrolled. During the initial hospi-
talization, a diagnosis of secondary hypertension was ruled out by
the presence of normal routine blood chemistry (including renal,
thyroid, and liver function) urine analysis, plasma aldosterone,
renin activity and urinary excretion of catecholamines and vanil
mandelic acid. When clinically indicated, a three-dimensional
phase contrast magnetic resonance angiography of the renal
arteries and magnetic resonance of the suprarenal glands were
also performed. Five patients showed evidence for a detectable
secondary cause for hypertension (two primary aldosteronism,
one renal parenchymal disease, and two renovascular hyperten-
sion), and were subsequently excluded from the study.
Study protocols
The study protocol is shown in Figure 1. Throughout the study,
the subjects were on a hospital diet, which was similar to the
controlled diet recommended during the previous month, contain-
ing a constant amount of protein (1.3 g/kg body wt), calories (30
kcal/kg body wt), calcium (800 mg), potassium (80 mEq) and
sodium (150 mEq). Twenty-four-hour urine samples and blood
were obtained at day 0 at about 8 a.m., when the patient arrived
at the hospital with the urine of the last day of controlled diet in
order to verify the compliance to the diet. Urine collection was
also performed on days 2 (on hospital diet), 4 (the day after
furosemide administration), and 5 (the day of Na load), for
measurement of sodium (UNaV) and potassium (UKV) excretion.
Creatinine clearance (CCr) on days 0 and 2, corrected to a body
surface area of 1.73 m2, was taken as an index of glomerular
filtration rate (GFR). GFR and the clearance of sodium CNa were
used for the calculation of fractional excretion of sodium (the
percentage of filtered sodium that escapes reabsorption) FENa 5
CNa/GFR.
Blood pressure was measured with a standard mercury sphyg-
momanometer by the same investigator (M.D. or L.B.) in the
individual patient throughout the study. Each data point of blood
pressure is the mean of at least three consecutive readings. Mean
arterial pressure (MAP) was calculated as the sum of diastolic
pressure plus one third of pulse pressure.
Two patients with urinary sodium excretion on day 0 of 2 . 250
mEq/24 hr (325 6 23 mEq/24 hr) and two patients with blood
pressure values of , 130/85 during the hospitalization were
excluded from the study.
All selected hypertensive patients were characterized for the
a-adducin polymorphisms, but the clinical researchers were un-
aware of the a-adducin genotype status of the patients.
On days 3 and 5, the patients were asked to void the bladder,
and assume the supine position between 7:00 and 8:00 a.m., in a
Fig. 1. Study protocol, where hypertensive
patients were admitted to the hospital for six
days. Urine and blood samples were collected
on day 1, during controlled diet, on day 3,
during hospital diet, on day 4, after furosemide,
and on day 5 during the Na load. The
furosemide test and Na load test were
performed on days 3 and 5, as detailed in the
Methods section.
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quiet comfortable room, and one venous catheter was inserted
into an antecubital vein. They remained in the supine position
throughout the studies except for voiding. Patients then received
a light breakfast (no coffee or tea). Between 8 and 9:00 a.m. the
patients drank an oral water load of 5 ml/kg. They were asked to
empty the their bladder spontaneously every 30 minutes. After
voiding, an equivalent amount of water was given orally to ensure
a high urine output. After a 60-minute equilibration period,
several 30-minute baseline measurements were performed until
the patients were in a steady state. Steady state was considered to
be achieved when the volume of two consecutive 30-minute urine
collections and the values of the mean blood pressure recordings
varied less than 1 ml/min or 3 mm Hg, respectively. Thus, the
average equilibration period lasted about two hours. The Na and
K content of the urine collected during the last 30 minutes were
measured.
Protocol 1: Furosemide test. This part of the study was carried
out on day 3. After the equilibration period and steady state
achievement, all subjects were given furosemide (25 mg p.o).
Urine was collected at the end of equilibration period, immedi-
ately before furosemide, and for the following 240 minutes (t 240).
Blood pressure was measured every 60 minutes, for three times at
three minute intervals, throughout the study (t 240). Blood sample
for serum sodium, and potassium determination were collected at
time 240 minutes.
Protocol 2: Acute salt loading test. This part of the study was
carried out on day 5. Following the equilibration period and
steady state achievement, 2 liters of i.v. saline (Na 310 mmol) were
infused in two hours. Blood pressure was measured every 30
minutes during the two hours of loading, and for three times at
three minutes interval at the end of the infusion (t 120). These last
three blood pressure values were averaged. The patient was then
allowed to rest and have lunch. Blood and urinary samples were
collected at the end of equilibration period, at the end of load, and
until 8 a.m. of day 6, for sodium and potassium determination.
Determination of the pressure-natriuresis relationship
The pressure-natriuresis relationship was obtained by plotting
the urinary sodium excretion rate (UNaV, in mmol/min) on the y
axis as a function of MAP (mm Hg) on the x axis measured under
two different sodium balance. Na excretion and the averaged
blood pressure during the last 30-minute equilibration period
were used as baseline values. Both variables were also obtained
after 240 minutes (t 240) of furosemide administration in the first
protocol, and at the end of the sodium load (t 120) in the second
protocol. The urine collected during the entire period was used to
calculate the sodium excretion rate, while the average of the three
measurements at the end of the period was taken as a final blood
pressure value achieved by the maneuvers. To compare the major
characteristics of the relationship, namely, the shift of the rela-
tionship along the arterial pressure axis and the slope of the
relationship, we calculated the extrapolated x intercept, A (mm
Hg), and the slope, B (mmol/min/mm Hg) as follows [3, 19, 20]:
A 5
@UNaV~H!] 3 [MAP(L)] 2 [UNaV(L)] 3 [MAP(H)]
UNaV(H) 2 UNaV(L)
B 5
UNaV~H! 2 UNaV~L!
MAP~H! 2 MAP~L!
where L and H are the data obtained during the equilibration
period and at the end of either test (time 240 for furosemide test
and time 120 for Na load, respectively). As pointed in the
introduction, animal data were produced by analyzing the changes
of Na excretion as a function of blood pressure, however, in
humans chronic and acute studies are performed by analyzing the
blood pressure changes as a function of Na intake (and/or Na
balance). For this reason the reciprocal of the slope (1/b in mm
Hg/mmol Na) is most commonly used as a more correct index of
the pressure-natriuresis relationship [3, 19, 20]. This calculation
has been proposed to analyze the relationship between Na
excretion and blood pressure in steady state, while in this study we
use the cumulative Na excretion during the sodium load or
furosemide action. The characteristics of the relationship should,
however, not be qualitatively different from those obtained in
steady state conditions. We deliberately chose this experimental
protocol in order to avoid the influence of a variety of environ-
mental and physiological factors on blood pressure, which may
change from one week to the other, as required to reach the
steady state after a change in Na intake, and to minimize the error
in urine collections or other types of stress that may arise from
more frequent collections of urine.
Analytic methods
Plasma renin activity and aldosterone were measured by radio-
immunoassay.
Urinary and plasma sodium, and potassium were determined by
flame photometry. Creatinine was determined by autoanalyzer.
Genotyping for adducin variant
Genomic DNA was isolated from 3 ml of whole blood by a
modified standard procedure [21]. The G460W polymorphism was
investigated by PCR amplification of genomic DNA followed by
allele specific oligonucletide hybridization. Genomic DNA (100
ng) was subjected to amplification using the following primers:
59GACAAGATGGCTGAACTCTGG 39 and 59AGTCTTC-
GACCTGGGACTGC 39 in a total volume of 30 ml containing 10
mM Tris-HCl (pH 8.8), 50 mM KCl, 1.5 mM MgCl2, 0.1% Triton
X-100, 15 pmol of each primer, 200 mM of dNTP, 1U Taq
Polymerase. The polymerase chain reaction (PCR) product was
79 bp. Allele specific oligonucleotide hybridization for the probe
for the wild type allele was 59 TTCTGCCCTTCCTC 39, and the
probe for the mutated allele (W variant) was 59 TTCTGCCAT-
TCCTC 39. They were labeled by T4 polynucleotide kinase and
used for hybridization in 5 3 SSC, 46°C, for two hours. The filters
are washed in 3 3 SSC for the wild type probe, at 46°C, and 5 3
SSC for the mutated probe at 46°C.
Statistical analysis
All clinical parameters are expressed as mean (6 SEM). Aver-
ages of blood pressure values and anthropometric variables were
compared with Student’s t-test. Statistical analysis was performed
using SPSS (version 6) statistical software.
RESULTS
The 108 patients studied were divided into distinct groups
according to the a-adducin genotype, and the genotype frequen-
cies observed were: 74% (N 5 80) G/G, 24% (N 5 26) G/W, and
2% (N 5 2) W/W. This was similar to that expected from the
allele frequencies according to the Hardy-Weinberg equilibrium
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for a sample of the same ethnic origin [17]. Since the W/W
genotype is relatively rare, the two homozygous for the a-adducin
variant were included in the analysis in the G/W-W/W group.
The clinical characteristics of 80 G/G and 28 G/W-W/W
hypertensive patients are described in Table 1. Homozygous and
heterozygous patients were similar for all the anthropometric
parameter considered. Blood pressure values both during 24-hour
ABPM (MAP G/G 115.3 6 1.5 and G/W-W/W 119.3 6 1.9 mm
Hg) and during days 1 and 2 of hospitalization were similar in the
two groups (Table 1). All the other clinical characteristics consid-
ered were not significantly different between the two groups.
On day 0, GFR was significantly higher while fractional Na
excretion was significantly lower in G/W-W/W heterozygous than
in G/G wild-type homozygous patients. On day 2 these differences
were in the same direction but were not statistically significant.
In spite of similar basal Na intake, measured as 24-hour urinary
Na excretion, plasma renin activity was significantly lower in
G/W-W/W hypertensives.
Urinary sodium and potassium excretion
Urinary sodium and potassium excretions are shown in Figure
2. Before furosemide test (day 2) both groups excreted the same
amount of Na as at the end of the controlled Na diet (day 0). Vice
versa, on the day preceding the sodium load (day 4) both groups
had a significantly lower urinary sodium as a result of the sodium
depletion with furosemide on day 3. Therefore, both groups of
patients started the study protocols from a similar sodium bal-
ance. Of course, by day five, after high Na intake, both groups had
an increased Na excretion. G/W-W/W patients increased their
urinary K excretion more than G/G (52.3 6 4.3 vs. 41.4 6 1.5
mEq/day, P , 0.01) on day 4, after the furosemide test.
Protocol 1: Pressure-natriuresis curve during the furosemide
test
At baseline of the furosemide test all of the parameters
examined were similar in the two groups (Table 2). Urinary
excretion of Na was similar in G/W-W/W and in G/G patients,
while urinary excretion of K was lower in G/W-W/W patients.
After furosemide the fall in plasma K (D 5 baseline 2 time 240
minutes), was greater in G/W-W/W patients. On the contrary, the
changes in urinary K excretion tended to be lower in the G/W-
W/W group, though the difference was not statistically significant
(P 5 0.09). We also observed a trend to a lower MAP after
Table 1. Major clinical variables of the patients who underwent the
furosemide test and acute salt loading test divided according to their
genotype for a-adducin (80 G/G, wild-type homozygous; 28 G/W-W/W,
heterozygous)
Variable G/G G/W-W/W P
Age years 42.6 6 1.1 44.1 6 1.5 ns
Duration of hypertension years 3.7 6 0.7 3.6 6 0.7 ns
Sex male/female 71/9 23/5 ns
BMI kg/m2 25.4 6 0.3 26.2 6 0.6 ns
MAP mm Hg 115.0 6 1.1 117.4 6 2.3 ns
Plasma K mEq/liter 4.19 6 0.03 4.15 6 0.06 ns
UKV mEq/24 hr 59.7 6 2.3 65.5 6 3.3 ns
UNaV day 0 mEq/24 hr 183.7 6 8.9 158.9 6 11.2 ns
UNaV day 2 161.8 6 6.7 143.9 6 8.1 ns
UNaV average 172.1 6 6.6 151.4 6 8.1 ns
CCr day 0 ml/min/1.73 m
2 115 6 2.4 126.3 6 4.5 0.03
CCr day 2 113.9 6 2.4 118.1 6 5.0 ns
CCr average 114.4 6 2.2 124.1 6 2.9 0.05
FENa % day 0 0.66 6 0.027 0.53 6 0.04 0.02
FENa % day 2 0.59 6 0.025 0.54 6 0.025 ns
FENa % average 0.62 6 0.022 0.53 6 0.025 0.03
Plasma aldosterone, clino ng/dl 13.8 6 1.2 14.5 6 0.9 ns
PRA, clino ng/ml/hr 1.15 6 0.10 0.74 6 0.097 0.015
Abbreviations are: BMI, body mass index; MAP, mean arterial pres-
sure; CCr, creatinine clearance; FENa, fractional clearance of sodium;
clino, standing body position; PRA, plasma renin activity.
UNaV and UKV, urinary sodium and potassium excretion; average is the
average values of day 0 and day 2.
Fig. 2. Urinary sodium (A) and potassium (B) excretion during the six
day hospitalization in the two groups of patients divided according to the
a adducin genotype (G/G, N 5 80, M; G/W-WW, N 5 28, f). In both
groups the UNaV was similar. However, UKV was significantly higher
(*P , 0.01) in the G/W-W/W patients on day 4 after the furosemide test.
Data are expressed as mean 6 SEM.
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furosemide in the G/W-W/W patients (from 118.8 6 2.1 to
115.1 6 2.5 mm Hg, P 5 0.109).
Figure 3 shows the pressure-natriuresis relationship obtained,
as indicated in the Methods section, by plotting UNaV before and
after furosemide on the y axis as a function of MAP on the x axis,
in G/W-W/W and G/G hypertensives. The reciprocal of the slope
of G/W-W/W patients (20.011 6 0.004 mm Hg/mmol) was
significantly different (P , 0.03) from that of G/G patients
(20.002 6 0.002 mm Hg/mmol).
Protocol 2: Pressure-natriuresis relationship during the acute
salt loading test
MAP values and urinary sodium excretion were lower at
baseline in both groups than those reported the first day, probably
as a consequence of Na depletion in day 3 caused by furosemide
administration (Table 3). Urinary sodium excretion and blood
pressure were measured before and after saline infusion (t 120
min). The increase in MAP levels produced by sodium load was
greater while the urine volume was lower in G/W-WW than in
G/G patients. The urinary sodium excretion after the Na load was
significantly lower (P , 0.03) in G/W-W/W (296 6 22.6 mmol/
min) than in G/G (393 6 24.4 mmol/min).
The pressure natriuresis relationship was obtained, as indicated
in the Methods section, by plotting urinary Na excretion on the
ordinate as a function of MAP in the abscissa, in G/W-W/W and
G/G hypertensives. As shown in Figure 4, the reciprocal of the
slope of the renal function curve in G/W-W/W (0.086 6 0.02 mm
Hg/mmol/min) was significantly (P , 0.001) different from that of
G/G patients (0.020 6 0.007 mm Hg/mmol/min), The extrapolate
X intercept, A, was significantly (P , 0.01) lower in G/W-W/W
(99.8 6 4.9 mm Hg) than in G/G (110.1 6 1.8 mm Hg) patients.
This indicates that the critical level of blood pressure below which
the urinary Na excretion is halted, is lower in G/W-W/W than in
G/G.
Relationship between changes in body sodium and blood
pressure
After both maneuvers, the variation in body sodium may be
calculated either by subtracting the sodium excreted from the
sodium infused or simply by subtracting the amount of sodium
excreted after furosemide.
Figure 5 shows the relationship between the variation in body
sodium after either depletion (furosemide) or load and the
corresponding blood pressure levels in the two groups of patients.
The slopes obtained were significantly different in the two groups
(G/W-W/W 0.029 6 0.004 vs. G/G 0.007 6 0.002, P 5 0.0001). For
the same degree of variation in body sodium, the magnitude of
blood pressure changes is greater in G/W-W/W than in G/G
patients clearly demonstrating that the former have a regulation
of blood pressure that is very sensitive to variations in total body
sodium.
DISCUSSION
These findings show that the patients with the 460W ‘hyperten-
sive’ variant when compared to the patients with G/G genotype
display: (1) a lower plasma renin activity and fractional excretion
of Na in basal conditions; (2) a decrease in the slope of the
pressure natriuresis relationship after acute furosemide adminis-
tration or saline load; and (3) a greater change in blood pressure
for a given modification of body Na.
These studies were carried out at a sodium intake considered to
be “normal” for these patients to avoid the fluctuations of the
homeostatic mechanisms involved in body Na control [22–26].
Table 2. Systemic and renal parameters before and after furosemide
Variable
G/G G/W-W/W P
Baseline D Baseline D Baseline D
MAP mm Hg 116.1 6 1.3 20.68 6 0.7 118.4 6 2.4 22.99 6 1.5 NS NS
Urine vol ml/min 3.15 6 0.2 5.02 6 0.2 3.14 6 0.4 5.17 6 0.3 NS NS
UNaV mmol/min 175.7 6 11.1 445.6 6 21 183.1 6 22.1 440.2 6 33.6 NS NS
UK V mmol/min 68.9 6 3.8 42.6 6 5.5 85.3 6 10.3 26.2 6 7.7 0.05 0.09
Plasma K mEq/liter 4.16 6 0.04 20.03 6 0.04 4.12 6 0.09 20.18 6 0.06 NS 0.05
Changes in systemic and renal parameter in G/G and G/W-W/W hypertensive patients at baseline and 240 minutes after furosemide administration
(t 240). The delta equation is: D 5 baseline 2 t 240 values. Data are mean 6 SEM. Abbreviations are: P Baseline, significance between the two groups
at baseline; P D, significance between the two groups after furosemide; MAP, mean arterial pressure; UNaV and UKV, urinary sodium and potassium
excretion, respectively.
Fig. 3. Renal pressure-natriuresis relantionships during furosemide ad-
ministration in 28 G/W-W/W (F) and 80 G/G (E) hypertensive patients.
Urinary sodium excretion rate (UNaV) was plotted on the ordinate as a
function of systemic mean arterial pressure (MAP) on the abscissa. The
reciprocal of the slope in G/W-W/W hypertensives was significantly
different (P , 0.03) from that of G/G hypertensive patients.
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Moreover, particular attention was devoted to minimizing the
influence of the sympathetic drive to the kidney, which may affect
renal function [27, 28]. This was achieved by performing the
critical measurements of BP and Na excretion after a period of
time that allowed good familiarization of the patients with the
environment and the investigators during such measurements,
and by avoiding clear differences in posture. Probably one of the
causes responsible for the contrasting results on renal function
changes in prehypertensive or hypertensive phases in the litera-
ture may be ascribed to variations in the experimental conditions,
which may have caused different degrees of symphatethic drive to
the kidney [29, 30]. We have to recognize that, when measuring
the pressure-natriuresis relationship, the Na excretion was calcu-
lated in the urine collected during the entire period of load (120
min) or depletion (240 min), while the blood pressure value was
taken at the end of this period. Clearly, this experimental proce-
dure is not appropriate to measure this relationship at steady state
conditions [1, 3], and it may underestimate the degree of changes
in the pressure-natriuresis relationship. However, we chose these
conditions to minimize the errors in the urine collection and the
stimuli of postural changes [31]. The pressure natriuresis refers to
the effect of blood pressure changes on a change in sodium
excretion. Such a phenomenon cannot be demonstrated directly in
humans. An attempt to circumvent this problem was to change the
Na balance and observe the concomitant changes in blood pres-
sure [3]. Our sole scope was to evaluate possible changes in blood
pressure caused by acute variation in body volumes in patients
with and without the 460W hypertensive variant.
The lower fractional Na excretion, slope of the pressure-
natriuresis relationship, and plasma renin in the subjects with the
“hypertensive” W variant indicate a faster tubular Na reabsorp-
tion as the cause of the renal function differences between the two
groups of patients. The higher GFR in patients with the W variant
is not a consistent findings [17]. However, in the present experi-
mental conditions, where particular care was devoted to minimize
Table 3. Systemic and renal parameters before and after acute salt loading
Variable
G/G G/W-W/W P
Baseline D Baseline D Baseline D
MAP mm Hg 112.8 6 1.1 2.2 6 0.7 110.5 6 1.7 8.05 6 1.2 ns 0.0001
Urinary vol ml/min 7.2 6 0.4 1.4 6 0.4 8.6 6 1.0 21.8 6 0.8 ns 0.0001
UNaV mmol/min 161.0 6 8.5 239.6 6 19 158.5 6 17.6 137.6 6 22 ns 0.005
UKV mmol/min 71.5 6 4.4 0.49 6 4.3 77.4 6 9.3 211.2 6 7.2 ns 0.08
PRA ng/ml/hr 1.3 6 0.13 20.19 6 0.3 0.81 6 0.10 20.11 6 0.1 0.05 n.s.
Changes in systemic and renal parameter in G/G and G/W-W/W hypertensive patients at baseline and at the end of the Na load (t 120). D 5
baseline 2 t 240 values. Data are mean 6 SEM. Abbreviations are: P Baseline, significance for comparisons between the two groups at baseline; P D,
significance for comparisons between the two groups after Na load; MAP, mean arterial pressure; UNaV and UKV, urinary sodium and potassium
excretion; PRA, plasma renin excretion.
Fig. 4. The pressure-natriuresis relationship in hypertensive patients
divided according to the a adducin genotype during an acute Na load. The
pressure natriuresis relationship was obtained, as indicated in the Methods
section, by plotting urinary Na excretion (UNaV) on the ordinate as a
function of MAP in the abscissa. The reciprocal of the slope in 28
G/W-W/W (F patients was significantly (P , 0.001) decreased than that of
80 G/G (E) hypertensive patients.
Fig. 5. Relationship between changes in mean arterial pressure (MAP)
and changes in body sodium from baseline during Na depletion or load in
28 G/W-W/W (F) and 80 G/G (E) hypertensive patients. Body sodium was
calculated either by subtracting the sodium excretion from the sodium
load or simply by subtracting the amount of sodium excretion after
furosemide. The changes in MAP were calculated from the baseline of
each test. The slopes of the two curves were significantly different in the
two groups (P 5 0.0001).
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methodological errors or environmental variables, the results
obtained exclude a primary decrease of glomerular filtration in
patients with W variant as the cause of reduced slope of the
pressure-natriuresis relationship [1].
Adducin is present in many tissues [12, 13]. Therefore, its
variants may affect the function of such tissues, which in turn may
modify the renal function (including tubular reabsorption)
through some extrarenal mechanism. For instance, the brain and
the heart are very rich in adducin and we cannot rule out a renal
modification that is secondary to some changes in the function of
these organs. In fact, the expression of the mutant a-adducin in
these tissue may contribute to the regulation of long-term mech-
anisms involved in blood pressure control and/or contribute to
renal sodium handling control. However, besides mineralcorticoid
hormones, we are unaware of any extrarenal pressor factor or
mechanism that may increase tubular reabsorption producing a
concomitant increase in GFR [32]. On the other hand, in the
Milan hypertensive rats, where hypertension can be transplanted
with the kidney [33], the same pattern of renal function is present.
Also, in humans we found an increase in GFR in the phase
preceding the development of hypertension in a subgroup of
subjects [29], together with the observation that a positive family
history for hypertension of the donors affects the blood pressure
of a kidney recipient [34], even though, for obvious reasons, this
was not demonstrated in the same subjects. An additional argu-
ment supporting the notion of a primary increased tubular
reabsorption is that all the known extrarenal causes that may
produce hypertension through changes in tubular reabsorption
are very rare conditions and are very often accompanied by an
increased level of aldosterone and/or low serum potassium [35,
36]. Therefore, they could not account for the difference in
fractional Na excretion between the two groups of patients in the
presence of similar levels of aldosterone and serum potassium.
We deliberately maintained the term of increased tubular
reabsorption without distinguishing among the different portions
of the nephron (proximal, loop of Henle, distal and collecting
ducts), since we do not have sufficient data to address this issue.
However, the salt sensitivity of blood pressure in these patients
together with lower PRA favor the speculation that the distal
tubule is the portion of nephron involved in the phenomena we
are describing [1]. Moreover, renal K handling after furosemide
or acute Na loading differ in the two groups of patients. After
furosemide a greater fall in plasma K occurs during the four hours
of the test and is accompanied by lower urinary K excretion during
the period (Table 2). However, one day after furosemide (day 4,
Fig. 2) urinary K excretion is greater in G/W-W/W patients. The
most likely explanation for the changes in urinary K after furo-
semide is that the acute falls in plasma K decreased the tubular
potassium load. The change in plasma K is very likely due to a
shift from extracellular to intracellular compartment. The expla-
nation for this effect of furosemide in K distribution within the
fluid compartment is unknown at present and deserves further
investigation. The slightly lower K excretion in G/W-W/W pa-
tients during Na loading (Table 3) is very likely secondary to a less
distal Na delivery, as suggested by the lower Na excretion in this
patients.
We did not measure all of the possible renal function changes
during these tests, and therefore we cannot exclude that the
mutated adducin variant produces changes in other renal districts.
Glomerular pressure, for instance, which was suggested to be
different between salt sensitive and salt resistant patients [37–40],
was not measured here.
The large blood pressure variation for any given change in body
Na in G/W-W/W patients (Fig. 5) is in keeping with previous data
of higher sodium sensitivity in G/W-W/W compared to G/G
patients [17]. We cannot clearly exclude the involvement of
extrarenal factors in this process even though, for the reasons
given above, we do think they are likely. We can, however,
speculate about the possible cellular mechanism linking the
adducin polymorphism to the pressure-natriuresis relationship as
follows: it has been recently suggested that an increase in Na
excretion after the rise of renal perfusion pressure is accompanied
by a shift of the Na pump units from the basolateral plasma
membrane of the tubular cells to an intracellular membrane pool
[41]. This shift may then reduce the capacity of the proximal
tubule to reabsorb Na, thus leading to faster Na excretion and
with a consequent reduction of blood pressure. Transfection of
hypertensive adducin cDNA in tubular cells increases the Vmax of
the Na-K pump and the surface expression of Na pump units [15].
Therefore, it can be suggested that the hypertensive adducin
variant might slow down this process of internalization of the Na
pump units brought about by the increased perfusion pressure,
thus leading to a decrease of the slope of the pressure-natriuresis
relationship. However, human adducin variant is different from
rat variant. Therefore, the assumption that human hypertensive
W variant causes cellular effects similar to that of rat hypertensive
adducin variant must be proved with experiments of cDNA
transfection in the renal epithelial cell.
In conclusion, the findings discussed here are consistent with
the hypothesis that the pressure changes caused by the adducin
mutated variant may occur for an effect on tubular reabsorption.
However, we admit that our results do not clearly distinguish
between the intrarenal or extrarenal mechanisms responsible of
these tubular function modifications.
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APPENDIX
Abbreviations used in this article are: ABPM, ambulatory blood pres-
sure monitoring; BMI, body mass index; CCr, creatinine clearance; clino,
standing position; CNa, sodium clearance; FENa, fractional excretion of
sodium; GFR, glomerular filtration rate; K, potassium; MAP, mean
arterial pressure; MHS, Milan hypertensive strain; MNS, Milan normo-
tensive strain; Na, sodium; PRA, plasma renin activity; RBF, renal blood
flow clearance; UKV, urinary potassium excretion; UNaV, urinary sodium
excretion; UVol, urinary volume; wt, weight.
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